83. アジソン病 ［臨床試験数：17，薬物数：27（DrugBank：13），標的遺伝子数：6，標的パスウェイ数：17］
Searched query = "Addison disease", "Primary chronic adrenocortical insufficiency", "Autoimmune polyglandular syndrome", "Hypoparathyroidism Addison Monilia syndrome", "HAM syndrome", "Schmidt syndrome"
The queries were searched in Public_title, Scientific_title, and Condition of the data. Export date: 11/20/2019, 11/21/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03210545 | September 1, 2019 | 12 November 2018 | A Study of Markers of Glucocorticoid Effects in Patients With Addisons Disease (DOSCORT) | A Dose-response Study of Markers of Glucocorticoid Effects (DOSCORT): A Single-blinded, Randomized, 2-dose, Cross-over Study | Addison Disease | Drug: Dexamethasone | Göteborg University | Not recruiting | 20 Years | 60 Years | All | 30 | Phase 4 | Sweden | |
| 2 | NCT03793114 | September 26, 2018 | 27 May 2019 | Screening and Stimulation Testing for Residual Secretion of Adrenal Steroid Hormones in Autoimmune Addison's Disease | Residual Secretion of Adrenal Steroid Hormones in Addison's Disease | Primary Adrenal Insufficiency | Diagnostic Test: Cosyntropin stimulation test;Diagnostic Test: Baseline blood tests;Device: 30-hour ambulatory sampling of intestinal fluid | University of Bergen | Karolinska Institutet;Charite University, Berlin, Germany | Recruiting | 18 Years | 70 Years | All | 200 | N/A | Germany;Norway;Sweden |
| 3 | EUCTR2015-001090-40-GB | 22/06/2015 | 28 September 2015 | Effects of hydrocortisone injection into deltoid and thigh muscles | An Open Label, Non-Randomised study to investigate the effects of 100mg Intramascular Hydrocortisone Injection in the Deltoid and Upper Thigh Muscle during the state of hypocortisolaemia - Effects of 100mg Hydrocortisone inj into Deltoid & Thigh | Addison's Disease;Therapeutic area: Body processes [G] - Metabolic Phenomena [G03] | Trade Name: Efcortesol Product Name: Hydrocortisone Efcortesol & Solu-Cortef Pharmaceutical Form: Injection | The London Clinic | Authorised | Female: yes Male: yes | 8 | United Kingdom | ||||
| 4 | EUCTR2012-001104-37-GB | 06/10/2014 | 23 March 2015 | pulses study | Pulsed glucocorticoid replacement therapy for patients with adrenocortical insufficiency secondary to Addison’s disease and congenital adrenal hyperplasia - the pulses study | Addison's disease and Congenital Adrenal Hyperplasia MedDRA version: 17.0 Level: LLT Classification code 10011195 Term: Cortisol System Organ Class: 100000004848 MedDRA version: 17.0 Level: LLT Classification code 10020518 Term: Hydrocortisone System Organ Class: 100000004848 ;Therapeutic area: Diseases [C] - Hormonal diseases [C19] | Trade Name: hydrocortisone sodium phosphate Product Name: hydrocortisone sodium phosphate Pharmaceutical Form: Solution for injection/infusion INN or Proposed INN: hydrocortisone sodium phosphate CAS Number: 6000 74 4 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10- Pharmaceutical form of the placebo: Solution for injection/infusion Route of administration of the placebo: Subcutaneous use Trade Name: hydrocortisone Product Name: hydrocortisone Pharmaceutical Form: Capsule INN or Proposed INN: hydrocortisone CAS Number: 50-23-7 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use | University Hospitals Bristol NHS Foundation Trust | Authorised | Female: yes Male: yes | United Kingdom | |||||
| 5 | NCT02096510 | August 2014 | 9 January 2017 | Ultradian Subcutaneous Hydrocortisone Infusion in Addison Disease and Congenital Adrenal Hyperplasia | Ultradian Subcutaneous Hydrocortisone Infusion in Addison Disease and Congenital Adrenal Hyperplasia | Addison Disease;Adrenal Hyperplasia Congenital | Drug: Solu-Cortef;Drug: Cortef | Haukeland University Hospital | Recruiting | 18 Years | 65 Years | Both | 10 | Phase 1/Phase 2 | Norway | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 6 | NCT02152553 | May 2014 | 13 May 2019 | Biomarker(s) for Glucocorticoids | Protein/Metabolite Biomarker(s) for Glucocorticoid Action; an Experimental Trial in Patients With Adrenal Insufficiency | Addison Disease | Drug: Hydrocortisone;Drug: Placebo | Vastra Gotaland Region | Not recruiting | 20 Years | 60 Years | All | 11 | N/A | Sweden | |
| 7 | EUCTR2013-004189-33-NO | 28/11/2013 | 28 April 2014 | A trial comparing continuous subcutaneous hydrocortisone therapy with pulsatile subcutaneous hydrocortisone therapy in patients with Addison`s disease | ULTRADIAN SUBCUTANEOUS HYDROCORTISONE (USHI) INFUSION IN ADDISON’S DISEASE | Addison`s disease;Therapeutic area: Diseases [C] - Hormonal diseases [C19] | Trade Name: Solu-Cortef Pharmaceutical Form: Powder and solvent for solution for infusion Trade Name: Cortef 5 mg Pharmaceutical Form: Tablet | Haukeland University Hospital | Authorised | Female: yes Male: yes | 10 | Norway | ||||
| 8 | NCT01847690 | June 2013 | 19 February 2015 | Effect of Cortisol on Physical Exertion in Patients With Primary Adrenal Failure | Effect of Cortisol on Physical Exertion in Patients With Primary Adrenal | Addison Disease | Drug: Hydrocortisone | Haukeland University Hospital | Not recruiting | 18 Years | 70 Years | Female | 20 | Phase 2 | Norway | |
| 9 | EUCTR2012-001682-33-GB | 06/09/2012 | 30 April 2019 | Rescue of Addison’s disease 2 | Combined Immunotherapy and Trophic Adrenocortical Stimulation in New Onset Autoimmune Addison’s Disease - Rescue of Addison’s disease 2 (RADS2) | Autoimmune Addison's disease: autoimmune primary adrenal insufficiency MedDRA version: 16.1 Level: PT Classification code 10052381 Term: Primary adrenal insufficiency System Organ Class: 10014698 - Endocrine disorders MedDRA version: 16.1 Level: LLT Classification code 10001335 Term: Adrenal cortex insufficiency System Organ Class: 10014698 - Endocrine disorders MedDRA version: 16.1 Level: LLT Classification code 10001342 Term: Adrenal cortical hypofunction System Organ Class: 10014698 - Endocrine disorders ;Therapeutic area: Diseases [C] - Hormonal diseases [C19] | Trade Name: Mabthera infusion Product Name: Mabthera Infusion Product Code: Rituximab Pharmaceutical Form: Concentrate for solution for infusion Trade Name: Solu-Medrone Product Name: Solu-Medrone Product Code: Methylprednisolone Pharmaceutical Form: Powder for injection Trade Name: Synacthen Depot Product Name: Synacthen Depot Product Code: Tetracosactide acetate Pharmaceutical Form: Suspension for injection | Newcastle upon Tyne Hospitals NHS Foundation Trust | Not Recruiting | Female: yes Male: yes | 30 | Phase 2 | United Kingdom | |||
| 10 | EUCTR2009-018074-56-GB | 05/05/2010 | 3 December 2012 | Revival of autochthonous adrenocortical stem cells in autoimmune Addison’s disease (RoSA) - Revival of Stem cells in Addison's disease (RoSA) | Revival of autochthonous adrenocortical stem cells in autoimmune Addison’s disease (RoSA) - Revival of Stem cells in Addison's disease (RoSA) | Autoimmune Addison's disease MedDRA version: 9.1 Level: HLT Classification code 10001343 Term: Adrenal cortical hypofunction | Trade Name: Synacthen Depot Product Name: Synacthen Depot Pharmaceutical Form: Suspension for injection | Newcastle upon Tyne Hospitals NHS Foundation Trust | Not Recruiting | Female: yes Male: yes | 12 | United Kingdom | ||||
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 11 | NCT01063569 | February 2010 | 19 February 2015 | Glucocorticoid Treatment in Addison's Disease | Glucocorticoid Treatment in Addison's Disease | Addison's Disease | Drug: Solu-Cortef (hydrocortisone);Drug: Cortef (hydrocortisone) | Haukeland University Hospital | Not recruiting | 18 Years | 70 Years | Both | 33 | Phase 2/Phase 3 | Norway;Sweden | |
| 12 | EUCTR2007-003062-18-GB | 05/06/2008 | 19 March 2012 | Immunotherapeutic Rescue of steroidogenic function in autoimmune Addison’s Disease (RAD): Pilot study - Rescue of Addison's Disease (RAD) | Immunotherapeutic Rescue of steroidogenic function in autoimmune Addison’s Disease (RAD): Pilot study - Rescue of Addison's Disease (RAD) | Autoimmune Addison's disease (adrenocortical failure) MedDRA version: 9.1 Level: HLT Classification code 10001343 Term: Adrenal cortical hypofunctions | Trade Name: MabThera Product Name: MabThera Pharmaceutical Form: Concentrate for solution for infusion Trade Name: Solu-medrone Product Name: Solu-medrone Pharmaceutical Form: Powder for injection* | Newcastle upon Tyne Hospitals NHS Trust | Authorised | Female: yes Male: yes | 10 | United Kingdom | ||||
| 13 | NCT01271296 | April 2008 | 19 February 2015 | Effects and Interactions of Liquorice and Grapefruit on Glucocorticoid Replacement Therapy in Addison's Disease | Use of Liquorice and Grapefruit in Patients With Addison's Disease | Addison Disease | Dietary Supplement: Liquorice;Dietary Supplement: Grapefruit Juice | Haukeland University Hospital | Not recruiting | 18 Years | 80 Years | Both | 17 | N/A | Norway | |
| 14 | EUCTR2007-005170-30-FR | 08/12/2007 | 19 March 2012 | Pharmacocinétique de l’Hydrocortisone chez le patient ADdisonien : évaluation de la valeur prédictive de l’ACTH plasmatique pour la titration du traitement substitutif - PHAD | Pharmacocinétique de l’Hydrocortisone chez le patient ADdisonien : évaluation de la valeur prédictive de l’ACTH plasmatique pour la titration du traitement substitutif - PHAD | ADDISON'S DISEASE MedDRA version: 9.1 Level: LLT Classification code 10001130 Term: Addison's disease | Trade Name: hydrocortisone Roussel Product Name: HYDROCORTISONE ROUSSEL Pharmaceutical Form: Tablet | CHU CAEN | Authorised | Female: yes Male: yes | France | |||||
| 15 | EUCTR2005-001768-30-SE | 04/01/2006 | 19 March 2012 | Comparison of 2 and 4 doses hydrocortison substitution with regard to plasma concentration and quality of life. - CHEQ | Comparison of 2 and 4 doses hydrocortison substitution with regard to plasma concentration and quality of life. - CHEQ | We aim to study patients with cortisol deficiency caused by primary adrenal insufficiency (Addison’s disease of autoimmune origin). | Product Name: Hydrocortisone Pharmaceutical Form: Capsule* Pharmaceutical form of the placebo: Capsule* Route of administration of the placebo: Oral use | EM-kliniken | Authorised | Female: yes Male: yes | 12 | Sweden | ||||
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 16 | NCT00688987 | August 2000 | 19 February 2015 | The Hypothalamic-Pituitary-Adrenal (HPA) Axis as an Effector System in Weight Regulation | Cortisol, Central Obesity, and Insulin Resistance: Long Term Studies in Addison's Patients | Obesity;Addison's Disease | Drug: Hydrocortisone;Dietary Supplement: Isocaloric Diet | Oregon Health and Science University | Not recruiting | 18 Years | N/A | Both | 24 | N/A | United States | |
| 17 | NCT00004313 | August 1995 | 19 February 2015 | Phase III Randomized, Double-Blind, Placebo-Controlled Study of Dehydroepiandrosterone Replacement for Primary Adrenal Insufficiency | Addison's Disease | Drug: dehydroepiandrosterone | National Center for Research Resources (NCRR) | University of California, Los Angeles | Not recruiting | 18 Years | N/A | Both | 40 | Phase 3 |